parp
No description yet: the sentence for this tag has not been written. 8 records carry it: 8 people.
Related tags
8 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Alan D. D'Andrea Director, Susan F. Smith Center for Women's Cancers and Center for DNA Damage and Repair, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Mapped the Fanconi anaemia/BRCA DNA repair pathway and how tumours become resistant to PARP inhibitors. | Ovarian cancer | none | dna-repair, resistance | ||
Isabelle Ray-Coquard Professor of Medical Oncology, Centre Léon Bérard and Université Claude Bernard Lyon 1; President, GINECO · Centre Léon Bérard Led PAOLA-1, which showed olaparib plus bevacizumab helps women with HRD-positive ovarian cancer beyond BRCA carriers. | Ovarian cancer | none | ovarian, hrd | ||
Jonathan A. Ledermann Professor of Medical Oncology, UCL Cancer Institute; Consultant, UCLH · University College London Hospitals / UCL Cancer Institute Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer. | Ovarian cancer | none | ovarian, uk | ||
Kathleen N. Moore Associate Director of Clinical Research, Stephenson Cancer Center, University of Oklahoma · Stephenson Cancer Center, OU Health Led SOLO-1 and MIRASOL, which gave ovarian cancer a maintenance PARP inhibitor and its first ADC with a survival benefit. | Ovarian cancer | none | ovarian, adc, trialist | ||
Maha Hussain Genevieve E. Teuton Professor of Medicine and Deputy Director, Robert H. Lurie Comprehensive Cancer Center of Northwestern University · Robert H. Lurie Comprehensive Cancer Center of Northwestern University Led PROSPER and the PROfound survival analysis, and settled the intermittent hormone therapy question with SWOG 9346. | Prostate cancer | none | prostate, swog | ||
Robert L. Coleman Chief Scientific Officer, US Oncology Research; Gynecologic Oncologist, Texas Oncology · The US Oncology Network / US Oncology Research Gynaecologic oncologist who led ARIEL3 and GOG-0213, shaping PARP maintenance and secondary surgery in relapsed ovarian cancer. | Ovarian cancer | none | ovarian, surgery | ||
Talia Golan Director, Pancreatic Cancer Center, Sheba Medical Center · Sheba Medical Center Led POLO, the first biomarker-driven trial in pancreatic cancer, which brought olaparib to BRCA carriers. | Pancreatic ductal adenocarcinoma | none | pancreatic, brca | ||
Thomas Helleday Professor of Chemical Biology, Karolinska Institutet; Professor, University of Sheffield · Karolinska University Hospital Co-discovered that PARP inhibitors kill BRCA-deficient cells, the synthetic lethality behind olaparib and its successors. | none | none | synthetic-lethality, discovery |
